195 related articles for article (PubMed ID: 32186202)
21. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
Santoro A; Genov G; Spooner A; Raine J; Arlett P
Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
[TBL] [Abstract][Full Text] [Related]
22. Safety referral procedures clarified.
Prescrire Int; 2014 Dec; 23(155):304-5. PubMed ID: 25629154
[TBL] [Abstract][Full Text] [Related]
23. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
Felix T; Jordan JB; Akers C; Patel B; Drago D
Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
[TBL] [Abstract][Full Text] [Related]
24. Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021.
Grupstra RJ; Goedecke T; Scheffers J; Strassmann V; Gardarsdottir H
Clin Pharmacol Ther; 2023 Dec; 114(6):1285-1292. PubMed ID: 37634124
[TBL] [Abstract][Full Text] [Related]
25. Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication.
Varallo FR; Forgerini M; Herdeiro MT; de Carvalho Mastroianni P
Clin Ther; 2019 Mar; 41(3):598-603. PubMed ID: 30792075
[TBL] [Abstract][Full Text] [Related]
26. Signal detection activity on EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for Pharmacovigilance.
Monaco L; Melis M; Biagi C; Donati M; Sapigni E; Vaccheri A; Motola D
Expert Opin Drug Saf; 2017 Mar; 16(3):271-275. PubMed ID: 28094583
[TBL] [Abstract][Full Text] [Related]
27. A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States - 2007 to 2016.
Perry LT; Bhasale A; Fabbri A; Lexchin J; Puil L; Joarder M; Mintzes B
Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1054-1063. PubMed ID: 32696556
[TBL] [Abstract][Full Text] [Related]
28. Identifying Safety Subgroups at Risk: Assessing the Agreement Between Statistical Alerting and Patient Subgroup Risk.
Mahaux O; Powell G; Haguinet F; Sobczak P; Saini N; Barry A; Mustafa A; Bate A
Drug Saf; 2023 Jun; 46(6):601-614. PubMed ID: 37131012
[TBL] [Abstract][Full Text] [Related]
29. [Direct reporting by patients of adverse drug reactions in Spain].
Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
[TBL] [Abstract][Full Text] [Related]
30. Biosimilars: pharmacovigilance and risk management.
Zuñiga L; Calvo B
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
[TBL] [Abstract][Full Text] [Related]
31. Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs.
Mazzaglia G; Straus SMJ; Arlett P; da Silva D; Janssen H; Raine J; Alteri E
Drug Saf; 2018 Feb; 41(2):191-202. PubMed ID: 29124666
[TBL] [Abstract][Full Text] [Related]
32. Navigating stormy waters: 10 years of operation of the European Union Regulatory Network Incident Management Plan for Medicines for Human Use.
Santoro A; Caplanusi I; Sweeney F; Cappelli B; Nolan L; Straus S; Arlett P
Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1343-1352. PubMed ID: 32954565
[TBL] [Abstract][Full Text] [Related]
33. Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADR.
Pierce CE; de Vries ST; Bodin-Parssinen S; Härmark L; Tregunno P; Lewis DJ; Maskell S; Van Eemeren R; Ptaszynska-Neophytou A; Newbould V; Dasgupta N; Wisniewski AFZ; Gama S; Mol PGM
Drug Saf; 2019 Apr; 42(4):477-489. PubMed ID: 30911975
[TBL] [Abstract][Full Text] [Related]
34. Post-approval safety issues with innovative drugs: a European cohort study.
Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
[TBL] [Abstract][Full Text] [Related]
35. Pharmacovigilance Discussion Forum--The European Generic Medicines Association's 8th Annual Meeting (January 21, 2015--London, UK).
Lam S
Drugs Today (Barc); 2015 Jan; 51(1):89-92. PubMed ID: 25685861
[TBL] [Abstract][Full Text] [Related]
36. European pharmacovigilance: increasingly outsourced to drug companies.
Prescrire Int; 2014 Dec; 23(155):302-3, 305-7. PubMed ID: 25629153
[TBL] [Abstract][Full Text] [Related]
37. Development of a novel regulatory pharmacovigilance prioritisation system: an evaluation of its performance at the UK Medicines and Healthcare products Regulatory Agency.
Seabroke S; Wise L; Waller P
Drug Saf; 2013 Oct; 36(10):1025-32. PubMed ID: 23821159
[TBL] [Abstract][Full Text] [Related]
38. Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET).
Bahri P; Morales DR; Inoubli A; Dogné JM; Straus SMJM
Drug Saf; 2021 Feb; 44(2):193-209. PubMed ID: 33125664
[TBL] [Abstract][Full Text] [Related]
39. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
[TBL] [Abstract][Full Text] [Related]
40. Pharmacovigilance in Israel - tools, processes, and actions.
Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
